InfuSystem (NYSE:INFU) Upgraded to “Strong-Buy” by B. Riley

B. Riley upgraded shares of InfuSystem (NYSE:INFU) to a strong-buy rating in a report published on Wednesday morning, Zacks.com reports.

Separately, StockNews.com raised shares of InfuSystem from a buy rating to a strong-buy rating in a research report on Friday, September 20th.

InfuSystem Stock Performance

Shares of NYSE:INFU opened at $6.75 on Wednesday. The firm has a market cap of $143.74 million, a P/E ratio of -675,000.00 and a beta of 1.46. The company has a current ratio of 2.07, a quick ratio of 1.64 and a debt-to-equity ratio of 0.64. InfuSystem has a 12 month low of $5.74 and a 12 month high of $10.99.

InfuSystem (NYSE:INFU) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The firm had revenue of $33.70 million during the quarter. InfuSystem had a net margin of 0.28% and a return on equity of 0.70%.

Institutional Trading of InfuSystem

Large investors have recently added to or reduced their stakes in the company. Kings Path Partners LLC acquired a new stake in shares of InfuSystem in the second quarter valued at approximately $514,000. First Eagle Investment Management LLC lifted its holdings in shares of InfuSystem by 12.7% during the first quarter. First Eagle Investment Management LLC now owns 605,235 shares of the company’s stock worth $5,187,000 after buying an additional 68,021 shares in the last quarter. Sequoia Financial Advisors LLC bought a new stake in InfuSystem in the 2nd quarter valued at about $272,000. Squarepoint Ops LLC bought a new stake in shares of InfuSystem in the second quarter valued at approximately $230,000. Finally, Ranger Investment Management L.P. lifted its position in shares of InfuSystem by 4.7% during the 4th quarter. Ranger Investment Management L.P. now owns 689,842 shares of the company’s stock valued at $7,271,000 after acquiring an additional 30,835 shares during the period. Institutional investors and hedge funds own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.